A Vision for the Future of Science Philanthropy
By Evan S. Michelson and Adam F. Falk,
Issues in Science and Technology
| 11. 09. 2021
Although we can envision many ways that the scientific enterprise might evolve in the future, an often-overlooked component will surely play an essential role: science philanthropy. By this we mean the provision of charitable giving for science or technology research by individual donors or foundations. As Robert Conn, past president and chief executive officer of The Kavli Foundation, details in his overview of the emergence of philanthropic giving for research, science philanthropy has always played a critical and leading role in America’s approach to research and development, with a history that predates much of the federal funding apparatus.
Today, the landscape of science philanthropy is rapidly changing. It consists of both established and newer foundations, a constellation of institutions including organizations with an illustrious history of giving for research as well as entities created more recently. Collectively, science philanthropy accounts for at least $2 billion in annual support for research. If we include spending from university endowments that supports research at those institutions, the total impact of philanthropy on science is estimated to be as much as $20 billion per...
Related Articles
By Matt Novak, Gizmodo | 07.23.2025
Robert F. Kennedy Jr., the Secretary of Health and Human Services, has made a big push to get agencies like the Food and Drug Administration to use generative artificial intelligence tools. In fact, Kennedy recently told Tucker Carlson that AI...
By Keith Casebonne and Jodi Beckstine [with CGS' Katie Hasson], Disability Deep Dive | 07.24.2025
In this episode of Disability Deep Dive, hosts Keith and Jodi explore the complex interplay between disability science, technology, and ethics with guest Katie Hasson, Associate Director at the Center for Genetics and Society. The conversation delves into...
By Angus Liu, Fierce Pharma | 07.22.2025
A brief skirmish between Sarepta Therapeutics and the FDA has ended before escalating into a full-on regulatory clash, as the company has bowed to the agency’s demand.
In a surprising reversal, Sarepta on Monday said it will pause all shipments...
By Lucy Tu, The Atlantic | 07.11.2025
Donald Trump—who is, by his own accounting, “the fertilization president” and “the father of IVF”—wants to help Americans reproduce. During his 2024 campaign, he promised that the government or insurance companies would cover the cost of in vitro fertilization. In...